Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
| Autor: | Robert G J Moes, Samuel J. P. Malkin, Tom Vandebrouck, Eline L. Huisman, Bruce H. R. Wolffenbuttel, Barnaby Hunt |
|---|---|
| Přispěvatelé: | Lifestyle Medicine (LM), Center for Liver, Digestive and Metabolic Diseases (CLDM) |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Pediatrics
medicine.medical_specialty Cost effectiveness Endocrinology Diabetes and Metabolism Population Type 2 diabetes CARDIOVASCULAR OUTCOMES VALIDATION MULTIFACTORIAL INTERVENTION MELLITUS medicine education LIXISENATIDE education.field_of_study COMPLICATIONS Insulin glargine Liraglutide business.industry Semaglutide Cost-effectiveness analysis medicine.disease OPEN-LABEL MODEL LIRAGLUTIDE Dulaglutide SULFONYLUREAS business medicine.drug |
| Zdroj: | BMJ Open Diabetes Research & Care, 7(1):000705. BMJ PUBLISHING GROUP |
| ISSN: | 2052-4897 |
| Popis: | ObjectiveChoosing therapies for type 2 diabetes that are both effective and cost-effective is vital as healthcare systems worldwide aim to maximize health of the population. The present analysis assessed the cost-effectiveness of once-weekly semaglutide (a novel glucagon-like peptide-1 (GLP-1) receptor agonist) versus insulin glargine U100 (the most commonly used basal insulin) and versus dulaglutide (an alternative once-weekly GLP-1 receptor agonist), from a societal perspective in the Netherlands.Research design and methodsThe IQVIA CORE Diabetes Model was used to project outcomes for once-weekly semaglutide 0.5 mg and 1 mg versus insulin glargine U100, once-weekly semaglutide 0.5 mg versus dulaglutide 0.75 mg, and once-weekly semaglutide 1 mg versus dulaglutide 1.5 mg. Clinical data were taken from the SUSTAIN 4 and SUSTAIN 7 clinical trials. The analysis captured direct and indirect costs, mortality, and the impact of diabetes-related complications on quality of life.ResultsProjections of outcomes suggested that once-weekly semaglutide 0.5 mg was associated with improved quality-adjusted life expectancy by 0.19 quality-adjusted life years (QALYs) versus insulin glargine U100 and 0.07 QALYs versus dulaglutide 0.75 mg. Once-weekly semaglutide 1 mg was associated with mean increases in quality-adjusted life expectancy of 0.27 QALYs versus insulin glargine U100 and 0.13 QALYs versus dulaglutide 1.5 mg. Improvements came at an increased cost versus insulin glargine U100, with incremental cost-effectiveness ratios from a societal perspective of €4988 and €495 per QALY gained for once-weekly semaglutide 0.5 mg and 1 mg, respectively, falling below Netherlands-specific willingness-to-pay thresholds. Improvements versus dulaglutide came at a reduced cost from a societal perspective for both doses of once-weekly semaglutide.ConclusionsOnce-weekly semaglutide is cost-effective versus insulin glargine U100, and dominant versus dulaglutide 0.75 and 1.5 mg for the treatment of type 2 diabetes, and represents a good use of healthcare resources in the Netherlands. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|